The Talbots Inc. (NYSE:TLB): Sycamore Partners will not be acquiring Talbots at this time, the latter company reported this morning. Shares of the retailer are down 88c (34.38) to $1.68 in mid-morning trading following the report that the (already twice-extended) exclusivity period with Sycamore was over. Talbots reports that it will pursue strategic alternatives, and is still willing to explore a transaction with Sycamore at $3.05 per share if that company can supply a suitable level of closing certainty and financing commitments. Talbots reported Q1 adjusted EPS of 9c, better than analysts’ estimates (2c) and revenue of $275.9M (above $272.54M consensus). Shares of Talbots traded at $1.61 recently, down $0.95 or 37.11%.
Hot Features: Here’s Why Dish Network is as DUMB as Congress.
Vimpel-Communications (NYSE:VIP) plans to appeal its expanded injunction order, but at the same time will attempt to reach a friendly resolution with appropriate regulators since the company was not immediately involved in the Telenor and Weather transaction. Vimpel is presently looking into the scope and possible impact of the expanded injunction on the VimpelCom Group’s overall business and financial position, present financing situations and future liquidity. Shares of the company traded down $1.02 (11.68%) lately, at $7.71.
Rosetta Genomics, Ltd. (NASDAQ:ROSG): The Oncologist has published data from studies of miRview mets2 in patients with Cancer of Unknown and Uncertain Primary. This study showed the potential of the miRview mets2 assay to pinpoint 42 tumor types with impressive accuracy and to hold the same performance in samples from patients clinically diagnosed with CUP, demonstrating an 88% agreement with the clinico-pathological evaluation of the patients. ROSG shares traded down 8.78% ($1.43) lately, at $14.86.
Don’t Miss: How Many Millions Did Citadel Lose on Facebook?
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.